Related Experiment Video
Updated: Jan 25, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Renal Sympathetic Denervation in Patients with Resistant Hypertension: A Feasibility Study
Kazuomi Kario1, Jose Ramon Rumoroso2, Yukie Okawara1
1Department of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Background/Aims:
We assessed the feasibility of renal sympathetic denervation (RDN) treatment in patients with resistant hypertension using the Iberis® RDN system. This study was a prospective, multicenter, single-arm feasibility registry.
Methods:
We collected data from patients who underwent RDN treatment using the Iberis system. From November 2014 to February 2016, 16 patients from 6 centers in Europe were enrolled in this registry.
Results:
Consistent reductions in the 24-h systolic blood pressure (SBP) and diastolic blood pressure were obtained. At any follow-up point, more than 70% of the patients were responders. The change in the 24-h SBP at 1 month was strongly correlated with that at 12 months.
Conclusion:
The Iberis system is safe and effective in patients for the treatment of resistant hypertension. Furthermore, our results suggest that we can estimate the effect of RDN in the long term at the 1-month follow-up point using the 24-h SBP.
More Related Videos
Related Concept Videos
The Sympathetic Nervous System
Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic Pathways: Sympathetic Chain Ganglia
Hypertension III: Clinical Manifestations and Diagnostic Studies
Sympathetic Activation
Serum Studies: Renal Function Tests

